SCHEMBL6344650

SCHEMBL6344650

CC(C)(C)[Si](C)(C)OCc1cc2cc(OCc3ccccc3)ccc2[nH]1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAOA P21397 4/20 0.56
MAOB P27338 3/20 0.56
KDM4E B2RXH2 1/20 0.52
ALDH1A1 P00352 1/20 0.52
CYP1A2 P05177 1/20 0.52
CYP2C9 P11712 1/20 0.52
HPGD P15428 1/20 0.52
SRD5A2 P31213 1/20 0.52
HSD17B10 Q99714 1/20 0.52
PDGFRB P09619 1/20 0.49
PDGFRA P16234 1/20 0.49
FLT3 P36888 1/20 0.47
ALOX5 P09917 1/20 0.46
NPC1 O15118 2/20 0.43
RAB9A P51151 2/20 0.43
LOXL2 Q9Y4K0 1/20 0.43
AURKA O14965 1/20 0.41
KDR P35968 1/20 0.41
TRPM8 Q7Z2W7 1/20 0.41
CFD P00746 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15717620 0.80 LOXL2 (0.47) KDM4EALDH1A1HPGDLOXL2
SCHEMBL29595819 0.80 LOXL2 (0.47) KDM4EALDH1A1HPGDLOXL2
SCHEMBL5093641 0.77 CYP1A2 (0.65) MAOAMAOBKDM4EALDH1A1CYP1A2
SCHEMBL400512 0.77 LOXL2 (0.62) MAOAMAOBKDM4EALDH1A1CYP1A2
SCHEMBL8187385 0.77 MAOA (0.59) MAOAMAOBKDM4EALDH1A1CYP1A2
SCHEMBL7677098 0.76 LOXL2 (0.51) KDM4EALDH1A1FLT3NPC1RAB9A
SCHEMBL5097564 0.76 ALDH1A1 (0.64) MAOAMAOBKDM4EALDH1A1CYP1A2
SCHEMBL4460706 0.75 KDM4E (0.53) KDM4EALDH1A1CYP1A2CYP2C9HPGD
SCHEMBL5123477 0.74 KDM4E (0.64) MAOAMAOBKDM4EALDH1A1CYP1A2
SCHEMBL15141030 0.74 SRD5A2 (0.68) MAOAMAOBKDM4EALDH1A1CYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6916841-B2 Inhibitors of phospholipase enzymes GENETICS INSTITUTE, LLC (US) 2005-07-12 US disclosed
US-6828344-B1 Direct inhibition of the activity of phospholipase A2 has been suggested as a useful mechanism for a therapeutic agent for inflammation GENETICS INSTITUTE, LLC 2004-12-07 US disclosed
US-20030153751-A1 Inhibitors of phospholipase enzymes AMERICAN HOME PRODUCTS CORPORATION 2003-08-14 US disclosed
EP-1056719-A2 INHIBITORS OF PHOSPHOLIPASE ENZYMES GENETICS INSTITUTE, INC. (US) 2000-12-06 EP disclosed
WO-1999043651-A2 INHIBITORS OF PHOSPHOLIPASE ENZYMES GENETICS INSTITUTE, INC. (US) 1999-09-02 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030153751-A1 Inhibitors of phospholipase enzymes PLA2G4C, PLA2G4B, PLA2G4A MAOA 847/4885MAOB 779/4885KDM4E 3586/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.